High-Dose Interleukin-2 Effective in mRCC Pre-Treated with VEGF-Targeted Therapies

Speaker: John Haanen

High-dose interleukin-2 can be effective in selected metastatic renal cell cancer patients pre-treated with VEGF-targeted agents, reveals research presented today at the ESMO Symposium on Immuno-Oncology in Geneva, Switzerland.

Discussion Points

  • What is interleukin-2 and how does it work?
  • How can we select patients that have a high chance of responding to interleukin-2?

Abstract Discussed

4O - Evaluating the place of interleukin-2 in the management of metastatic renal cell cancer (mRCC) in the era of targeted therapy